跳转至内容
Merck
CN
  • Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.

Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.

Hepatology (Baltimore, Md.) (2014-02-13)
Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja-Wyszomirska, Gideon M Hirschfield, Olivier Barbier, Piotr Milkiewicz
摘要

Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10-15 mg/kg/day) were included. Paired blood samples for liver biochemistry, bile acids, and fibroblast growth factor 19 (FGF19) were collected before UDCA withdrawal and 3 months later. Liquid chromatography/tandem mass spectrometry was used for quantification of 29 plasma bile acid metabolites. Pruritus and health-related quality of life (HRQoL) were assessed with a 10-point numeric rating scale, the Medical Outcomes Study Short Form-36 (SF-36), and PBC-40 questionnaires. UDCA withdrawal resulted in a significant deterioration in liver biochemistry (increase of alkaline phosphatase of 75.6%; P<0.0001; gamma-glutamyl transpeptidase of 117.9%, P<0.0001; bilirubin of 50.0%, P<0.001; alanine aminotransferase of 63.9%, P<0.005; and aspartate aminotransferase of 45.0%, P<0.005) and increase of Mayo Risk Score for PSC (change from baseline of +0.5 point; P<0.003). Bile acid analysis revealed a significant decrease in lithocholic acid and its derivatives after UDCA withdrawal, but no effect on concentrations of primary bile acids aside from an increased accumulation of their taurine conjugates. After UDCA removal cholestatic parameters, taurine species of cholic acid and chenodeoxycholic acid correlated with serum FGF19 levels. No significant effect on HRQoL after UDCA withdrawal was observed; however, 42% of patients reported a deterioration in their pruritus. At 3 months, discontinuation of UDCA in patients with PSC causes significant deterioration in liver biochemistry and influences concentrations of bile acid metabolites. A proportion of patients report increased pruritus, but other short-term markers of quality of life are unaffected.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
乙酸乙酯, ACS reagent, ≥99.5%
Sigma-Aldrich
乙酸, glacial, ACS reagent, ≥99.7%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
乙酸乙酯, suitable for HPLC, ≥99.7%
Sigma-Aldrich
乙酸, glacial, ReagentPlus®, ≥99%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
吡啶, ACS reagent, ≥99.0%
Sigma-Aldrich
正己烷, suitable for HPLC, ≥97.0% (GC)
Sigma-Aldrich
乙酸乙酯, HPLC Plus, for HPLC, GC, and residue analysis, 99.9%
Sigma-Aldrich
正己烷, ReagentPlus®, ≥99%
Sigma-Aldrich
正己烷, suitable for HPLC, ≥95%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
无水柠檬酸粉末, meets analytical specification of Ph. Eur., BP, USP, E330, anhydrous, 99.5-100.5% (based on anhydrous substance)
Sigma-Aldrich
正己烷, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99% (GC)
Sigma-Aldrich
乙酸, glacial, ≥99.99% trace metals basis
Sigma-Aldrich
吡啶, suitable for HPLC, ≥99.9%
Sigma-Aldrich
正己烷, HPLC Plus, for HPLC, GC, and residue analysis, ≥95%
Sigma-Aldrich
吡啶, anhydrous, 99.8%
Sigma-Aldrich
乙酸 溶液, suitable for HPLC
Sigma-Aldrich
乙酸, glacial, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8%
Sigma-Aldrich
乙酸, glacial, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.8-100.5%
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
无水柠檬酸粉末, ACS reagent, ≥99.5%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
吡啶, ReagentPlus®, ≥99%
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
正己烷, Laboratory Reagent, ≥95%